Approximately 20%-30% of individuals with MASLD progress to MASH, characterized by hepatocyte ballooning, lobular inflammation, and variable fibrosis, and 10%-20% of MASH patients develop advanced fibrosis (stages F3-F4) or cirrhosis over their lifetime [6,13]
Individuals with overweight or obesity and T2DM were found to have a lower body weight reduction of 9.6%
The semaglutide and tirzepatide trials changed that expectation: Semaglutide 2.4 mg once weekly produced average weight loss around 15% at ~68 weeks in adults without diabetes, with a substantial fraction of participants losing 1520% of baseline weight
Labs are not required to get started
A prescription is not a protocol
Retatrutide cons Still in clinical trials : Retatrutide is not approved yet and is still in trials so its not commercially available for general use